Search research articles
Contact Us
Filters
Showing results (681-690 of 703) with videos related to
Page
of 71
Sort By:
JAMA Oncology
|
March 9, 2023
Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer: The Phase 2 TBCRC041 Randomized Clinical Trial
Tufia C Haddad, Vera J Suman, Antonino B D'Assoro, et al.
Journal of the National Cancer Institute
|
December 7, 2023
Taxanes for the treatment of breast cancer during pregnancy: an international cohort study
Ana S Ferrigno Guajardo, Bryan F Vaca-Cartagena, Erica L Mayer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 7, 2021
Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131
Ingrid A Mayer, Fengmin Zhao, Carlos L Arteaga, et al.
The Lancet. Oncology
|
July 13, 2026
Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial
Nicholas C Turner, Erica L Mayer, Yeon Hee Park, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 19, 2023
Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030
H A Parsons, T Blewett, X Chu, et al.
Medrxiv : the Preprint Server for Health Sciences
|
March 22, 2023
Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030
Heather A Parsons, Timothy Blewett, Xiangying Chu, et al.
Cancer
|
January 18, 2024
Adjuvant platinum versus capecitabine for residual, invasive, triple-negative breast cancer: Patient-reported outcomes in ECOG-ACRIN EA1131
Karen L Smith, Fengmin Zhao, Ingrid A Mayer, et al.
JAMA Oncology
|
August 21, 2025
Impact of a Weight Loss Intervention on 1-Year Weight Change in Women With Stage II/III Breast Cancer: Secondary Analysis of the Breast Cancer Weight Loss (BWEL) Trial
Jennifer A Ligibel, Karla V Ballman, Linda McCall, et al.
The Lancet. Oncology
|
March 19, 2019
Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial
Panagiotis A Konstantinopoulos, William T Barry, Michael Birrer, et al.
Geophysical Research Letters
|
December 22, 2017
BedMachine v3: Complete Bed Topography and Ocean Bathymetry Mapping of Greenland From Multibeam Echo Sounding Combined With Mass Conservation
M Morlighem, C N Williams, E Rignot, et al.
Page
of 71
Search research articles
Search
Showing results (681-690 of 703) with videos related to
Sort By:
Page
of 71
JAMA Oncology
|
March 9, 2023
Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer: The Phase 2 TBCRC041 Randomized Clinical Trial
Tufia C Haddad, Vera J Suman, Antonino B D'Assoro, et al.
Journal of the National Cancer Institute
|
December 7, 2023
Taxanes for the treatment of breast cancer during pregnancy: an international cohort study
Ana S Ferrigno Guajardo, Bryan F Vaca-Cartagena, Erica L Mayer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 7, 2021
Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131
Ingrid A Mayer, Fengmin Zhao, Carlos L Arteaga, et al.
The Lancet. Oncology
|
July 13, 2026
Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial
Nicholas C Turner, Erica L Mayer, Yeon Hee Park, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 19, 2023
Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030
H A Parsons, T Blewett, X Chu, et al.
Medrxiv : the Preprint Server for Health Sciences
|
March 22, 2023
Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030
Heather A Parsons, Timothy Blewett, Xiangying Chu, et al.
Cancer
|
January 18, 2024
Adjuvant platinum versus capecitabine for residual, invasive, triple-negative breast cancer: Patient-reported outcomes in ECOG-ACRIN EA1131
Karen L Smith, Fengmin Zhao, Ingrid A Mayer, et al.
JAMA Oncology
|
August 21, 2025
Impact of a Weight Loss Intervention on 1-Year Weight Change in Women With Stage II/III Breast Cancer: Secondary Analysis of the Breast Cancer Weight Loss (BWEL) Trial
Jennifer A Ligibel, Karla V Ballman, Linda McCall, et al.
The Lancet. Oncology
|
March 19, 2019
Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial
Panagiotis A Konstantinopoulos, William T Barry, Michael Birrer, et al.
Geophysical Research Letters
|
December 22, 2017
BedMachine v3: Complete Bed Topography and Ocean Bathymetry Mapping of Greenland From Multibeam Echo Sounding Combined With Mass Conservation
M Morlighem, C N Williams, E Rignot, et al.
Page
of 71